Effects of alcohol (0.5 %0) and MDMA (100 mg) on (simulated) driving performance, driving related performance and traffic safety

This crossover study (n=20) aimed to assess the effects of a single dose of MDMA (100 mg) and/or alcohol (0.5%) on simulated driving performance.

Conducted by Rijksuniversiteit Groningen, it was part of the EU project DRUID to combat impaired driving. Subjects, aged between 21 and 40, were given various combinations of substances in a controlled experimental design.

The study, approved by the Medical Ethics Committee, started in April 2010 and enrolled 20 participants. It involved driving tests conducted post-drug intake and psychomotor tests afterwards.

The primary outcome was driving performance, with secondary outcomes including analyses of drug levels and questionnaire results. Contacts for the study were provided for both public and scientific inquiries.

The results of this trial can be found here.

Topic Healthy Subjects Safety
Compound MDMA
Country Netherlands
Visit trial
Status Completed
Results Published Yes
Start date 05 April 2010
End date 01 January 2011
Phase Not Applicable
Design Open
Type Interventional
Generation First
Participants 20
Sex All
Age 21- 40
Therapy No

Trial Details

This observational crossover study (n=20) examined the effects of MDMA (100 mg) and/or alcohol (0.5%) on simulated driving performance. Conducted by Rijksuniversiteit Groningen as part of the EU project DRUID, the study aimed to inform guidelines for combating impaired driving. It began in April 2010, enrolling 20 participants, and involved driving tests post-drug intake. Approved by the Medical Ethics Committee, the study's primary outcome was driving performance, with secondary outcomes including drug level analyses.

NCT Number 2008-001359-23

Sponsors & Collaborators

University of Groningen
The University of Groningen, established in 1614, is a prestigious institution that ranks among the world's top universities. It has taken a pioneering role in the interdisciplinary research of psychedelics, harnessing its rich academic heritage and a forward-looking approach to exploring the potential of psychedelic substances in treating various mental health conditions.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.